The Supreme Court Picks the Wrong Patent Fight in Hikma v. Amarin

Supreme Court will hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., addressing whether generic drug manufacturers can face inducement patent infringement liability based on marketing practices under "skinny label" approvals. The case involves Hikma's generic version of Amarin's Vascepa drug and questions whether compliance with FDA-approved labeling provides safe harbor from inducement claims, even if other conduct encourages infringing uses.